ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "ESMO 2024"
Episode Synopsis
Recapping just some of the notable data coming out of ESMO 2024:
-Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC)
-AMBASSADOR (adjuvant pembrolizumab in bladder cancer)
-NIAGRA (perioperative durvalumab in bladder cancer)
-ADRIATIC (discussed on ASCO recap Pod, but publication now available)
-LEANOX (impact of lean body mass adjustment on oxaliplatin dose)
-Final OS results from Keynote-522 (perioperative pembrolizumab in TNBC)
-AMBASSADOR (adjuvant pembrolizumab in bladder cancer)
-NIAGRA (perioperative durvalumab in bladder cancer)
-ADRIATIC (discussed on ASCO recap Pod, but publication now available)
-LEANOX (impact of lean body mass adjustment on oxaliplatin dose)
More episodes of the podcast OncoPharm
Bladder Cancer Updates & SC Amivantamab
18/12/2025
ASH 2025
11/12/2025
DPYD Deficiency Testing
04/12/2025
Cornucopia of Autumn Updates
26/11/2025
PGYNone: Dandelion Effect
20/11/2025
PGY1 Pathway: Road Trip!
13/11/2025
PGY2 Pathway: A Planned City
06/11/2025
Tale from the Crypt: Belantamab Mafodotin
30/10/2025
ESMO 2025
23/10/2025
IL-2
16/10/2025
In God we trust